Click here to download PDF Version of the final programme (1.8 MB)

Search through the abstracts in detail! Click here to start!

About the Agenda Builder

The agenda builder is a simple, light-weight tool to manage your schedule. There are filters to narrow your search by day, track and/or presenter.

  • To use, simply click the "Add to my agenda" link. The  selected item will remain in memory indefinitely. 
  • Limitation: It will only "remember" the computer employed AND as long as you do not erase your "cookies".

:   :   :

:   :   Search

HPV 2010
 
Programme

>> Day 5 - Wednesday, July 7, 2010

Time Description Room Expand all sessions
07:00 AM
Early-Morning Workshop - Young Researchers Community of Practice
 516bcd
 Show details
07:00 AM
    L   
How to Manage a Research Team
Nicolas Wentzensen
Investigator, Hormonal and Reproductive Epidemiology Branch, National Cancer Institute, Division of Cancer epidemiology & Genetics
, USA
516bcd
 Add to my agenda
07:00 AM
    L   
How to Manage a Research Team
Mark Schiffman [Bio]
Senior Investigator, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health
Rockville, USA
516bcd
 Add to my agenda
07:00 AM
    L   
How to Manage a Research Team
Phillip Castle [Bio]
Investigator, National Cancer Institute, National Institutes of Health
Bethesda, USA
516bcd
 Add to my agenda
07:00 AM
Early-Morning Workshop - Emerging Nations Capacity Building – PATH: Vaccine implemetation
 515ab
 Add to my agenda
07:00 AM
Early-Morning Workshop - Women of Influence – HPV Community Mobilization (by invitation only) Sponsored by Coalition Cancer / HPV Awareness Group
 525ab
 Add to my agenda
08:30 AM
Plenary - Natural History and Extragenital Infections
Chair(s):
Anna R. Giuliano, Tampa, USA
Marie-Hélène Mayrand, Montréal, Canada
 517cd
 Show details
08:30 AM
    L   
The natural history of papillomavirus disease; from silent and productive infections to neoplasia and latency
John Doorbar [Abstract]
Group Leader, Division of Virology, National Institute for Medical Research
London, United Kingdom
517cd
 Add to my agenda
09:00 AM
    L   
Current Knowledge and Gaps about HPV Natural History
Denise A. Galloway
Head, Cancer Biology Program; Member, Human Biology and Public Health Sciences Divisions; Fred Hutchinson Cancer Research Center
Seattle, USA
517cd
 Add to my agenda
09:30 AM
    L   
Molecular Basis of PV Oncogenecity
Magnus von Knebel Doeberitz [Abstract]
Director and Professor, Department of Applied Tumor Biology, University of Heidelberg Im Neuenheimer
Heidelberg, Germany
517cd
 Add to my agenda
10:30 AM
Oral Communications - Basic Science 7
Chair(s):
Thomas Iftner, Tuebingen, Germany
Thomas Iftner, Tuebingen, Germany
 517b
 Show details
10:30 AM
    L   
Interaction of the HPV E1 helicase with the WD repeat protein p80 is required for efficient viral DNA replication
Michaël Lehoux [Abstract]
Montreal, Canada
517b
 Add to my agenda
10:45 AM
    L   
Methylation-mediated silencing and tumour suppressive function of miR-124 in cervical cancer
Saskia M. Wilting [Abstract]
Amsterdam, The Netherlands
517b
 Add to my agenda
11:00 AM
    L   
A comparative interactomic analysis of E6 and E7 from eleven human papillomaviruses
Yves Jacob [Abstract]
Paris, France
517b
 Add to my agenda
11:15 AM
    L   
FA-Deficient Mice are Predisposed to HPV-Associated Cancers
Jung Wook Park [Abstract]
Madison, USA
517b
 Add to my agenda
11:30 AM
    L   
Genomic profiling of high-grade CIN lesions of women with and without 5 year preceding high-risk HPV infection
Mariska Bierkens [Abstract]
Amsterdam, the Netherlands
517b
 Add to my agenda
11:45 AM
    L   
Reprogramming the BPV E5 protein
Daniel DiMaio [Bio] [Abstract]
Waldemar Von Zedtwitz Professor and Vice Chairman of Genetics, Professor of Therapeutic Radiology, Scientific Director, Department of Genetics, Yale Cancer Center
New Haven, USA
517b
 Add to my agenda
10:30 AM
Oral Communications - Clinical Science 7
Chair(s):
Max Chernesky, Hamilton, Canada
Susanne Krüger Kjær, Copenhagen, Denmark
 517a
 Show details
10:30 AM
    L   
Increased burden of treatment of cervical intraepithelial neoplasia: Denmark 1991 to 2007
Sidsel S. Barken [Abstract]
Copenhagen , Denmark
517a
 Add to my agenda
10:45 AM
    L   
Evaluation of birth outcomes following treatment for precancerous changes to the cervix
Shantini Paranjothy [Abstract]
Carmarthen , UK
517a
 Add to my agenda
11:00 AM
    L   
HPV Testing of Women in British Columbia Following Excisional Therapy for CIN 2/3
Wendy Mei [Abstract]
Vancouver, Canada
517a
 Add to my agenda
11:15 AM
    L   
Risk on premature delivery after CIN treatment in a Belgian multicentric prospective study
Jérôme Antoine [Abstract]
Brussels, Belgium
517a
 Add to my agenda
11:30 AM
    L   
Effect of condom use after CIN treatment on HPV positivity and other biomarkers: a randomised controlled trial.
Maria Kyrgiou [Abstract]
London, UK
517a
 Add to my agenda
11:45 AM
    L   
A specific HPV type for each CIN lesion
W.G.V. Quint [Abstract]
Voorburg, The Netherlands
517a
 Add to my agenda
10:30 AM
Oral Communications - Epidemiology & Public Health 7
Chair(s):
Tom Wong, Ottawa, Canada
Zeev Rosberger, Montreal, Canada
 524
 Show details
10:30 AM
    L   
Male Circumcision Reduces HPV Infection in Female Partners in Rakai, Uganda
Patti Gravitt [Bio] [Abstract]
Assistant Professor, Epidemiology; Molecular Microbiology and Immunology, John Hopkins Bloomberg School Of Public Health(JHSPH)
Baltimore, USA
524
 Add to my agenda
10:45 AM
    L   
Age-specific occurrence of new HPV infection in a large population-based sample of women in Italy
Francesca Maria Carozzi [Abstract]
Florence, Italy
524
 Add to my agenda
11:00 AM
    L   
Men's Psychosocial Responses to HPV Test Results: Implications for Vaccine Promotion
Ellen Daley [Abstract]
Tampa, US
524
 Add to my agenda
11:15 AM
    L   
Evaluation of combined HPV vaccination and careHPV screening strategies in rural China
Ju-Fang Shi [Abstract]
Woolloomooloo, Australia
524
 Add to my agenda
11:30 AM
    L   
Model-based predictions of the impact of HPV immunization programs for males and catch-up programs for females
Chris T. Bauch [Abstract]
Guelph, Canada
524
 Add to my agenda
11:45 AM
    L   
HPV-16 SEROPREVALENCE IN A POPULATION-BASED SUB-SAMPLE OF PUERTO RICAN ADULTS
Ana Patricia Ortiz [Abstract]
San Juan, USA
524
 Add to my agenda
10:30 AM
Satellite Symposium - AIN and anal cancer- setting the research agenda
More Details...
Chair(s):
Joel Palefsky, San Francisco, USA
 515ab
 Show details
10:30 AM
    L   
Welcome and introduction
Joel Palefsky [Bio]
Professor of Medicine, UCSF School of Medicine
San Francisco, USA
515ab
 Add to my agenda
10:35 AM
    L   
Natural history of AIN and anal cancer
Joel Palefsky [Bio]
Professor of Medicine, UCSF School of Medicine
San Francisco, USA
515ab
 Add to my agenda
10:55 AM
    L   
Biology and pathogenesis of AIN
Sharof Tugizov
San Francisco, USA
515ab
 Add to my agenda
10:55 AM
    L   
Biology and pathogenesis of AIN - (DISCUSSANT)
François Coutlée [Bio]
Professor, Microbiology and Immunology, Université de Montréal
Montreal, Canada
515ab
 Add to my agenda
11:15 AM
    L   
Screening for AIN and anal cancer
Elizabeth A. Stier
Boston, USA
515ab
 Add to my agenda
11:15 AM
    L   
Screening for AIN and anal cancer - (DISCUSSANT)
J. Michael Berry
San Francisco, USA
515ab
 Add to my agenda
11:35 AM
    L   
Treatment of AIN
Stephen Goldstone
Department of Surgery, Mount Sinai School of Medicine
New York, USA
515ab
 Add to my agenda
11:35 AM
    L   
Treatment of AIN - (DISCUSSANT)
Mayura Nathan
London, United Kingdom
515ab
 Add to my agenda
11:55 AM
    L   
Summary
Richard Hillman
Westmead, Australia
515ab
 Add to my agenda
12:30 PM
Satellite Lunch Symposium - Sponsored by GSK - BECAUSE CERVICAL CANCER PREVENTION MATTERS
Chair(s):
Eduardo Franco, Montreal, Canada
Hugues Bogaerts, Belgium
 710
 Show details

   L   
Welcome and introduction
Eduardo Franco [Bio]
Professor and Director, Division of Cancer Epidemiology, McGill University
Montreal, Canada
710
 Add to my agenda

   L   
Cervical cancer vaccination: A compelling case
Swee Chong Quek
Singapore, Singapore
710
 Add to my agenda

   L   
Immunology of HPV infection: Implications for vaccine development
Lutz Gissmann
Head of the Division of Genome Modification, German Cancer Center
Heidelberg, Germany
710
 Add to my agenda

   L   
Cervical cancer vaccination: Clinical outcomes with Cervarix®
Fred Aoki
Winnipeg, Canada
710
 Add to my agenda

   L   
All about preventing more cervical cancers
Jack Cuzick [Bio]
John Snow Professor of Epidemiology, Head of Department, Cancer Research UK Centre for Epidemiology, Mathematics and Statistics, Queen Mary, University of London, Wolfson Institute of Preventive Medicine
London, United Kingdom
710
 Add to my agenda
02:00 PM
Oral Communications - Basic Science 8
Chair(s):
Raphael Viscidi, Baltimore, USA
Ingeborg Zehbe, Thunder Bay, Canada
 517b
 Show details
02:00 PM
    L   
Intact BPV-1 virion is required for experimental tumour induction in foals and causes viraemia
Edmund K. Hainisch [Abstract]
Wien, Austria
517b
 Add to my agenda
02:15 PM
    L   
Development of a Model of Papillomavirus Latency Following Immune Regression
John Doorbar [Abstract]
Group Leader, Division of Virology, National Institute for Medical Research
London, United Kingdom
517b
 Add to my agenda
02:30 PM
    L   
Canine Papillomavirus E7 uses a different domain to bind and destabilize Rb Protein
Hang Yuan [Abstract]
Washington, USA
517b
 Add to my agenda
02:45 PM
    L   
In vitro and in vivo immunogenicity of BPV1 E5 and E6 in a mouse model of equine sarcoids
Lies Bogaert [Abstract]
Los Angeles, USA
517b
 Add to my agenda
03:00 PM
    L   
Bovine papillomaviruses in the peripheral blood of cattle: expression in lymphocytes.
R.C Stocco [Abstract]
São Paulo, Brazil
517b
 Add to my agenda
03:15 PM
    L   
Rapamycin Decreases Growth of HPV-associated Anal Cancer: Assessment in Two Newly Developed Anal Cancer Mouse Models
Marie Stelzer [Abstract]
Madison, USA
517b
 Add to my agenda
02:00 PM
Oral Communications - Clinical Science 8
Chair(s):
Mark Stoler, Charlottesville, USA
 517a
 Show details
02:00 PM
    L   
The Rhine-Saar Study - a Randomized Trial Comparing Conventional Cytology to Computer-assisted Thinlayer Cytology
Hans Ikenberg [Abstract]
Frankfurt, Germany
517a
 Add to my agenda
02:15 PM
    L   
Primary HPV testing with different cutoff levels in comparison to cytology in population-based cervical screening
Dorien Rijkaart [Abstract]
Amsterdam, The Netherlands
517a
 Add to my agenda
02:30 PM
    L   
HPV testing in Cervical Cancer Screening: Evaluation of different screening strategies for HPV DNA positive women
Dorien Rijkaart [Abstract]
Amsterdam, The Netherlands
517a
 Add to my agenda
02:45 PM
    L   
Follow-up results of the ARTISTIC trial over three rounds of screening: a comparison of baseline LBC and HPV testing
Julian Peto [Abstract]
Keppel Street, UK
517a
 Add to my agenda
03:00 PM
    L   
Switch from Cytology-based to HPV-based Cervical Screening: Implications for Colposcopy
Carolina Porras [Abstract]
Rockville, United States
517a
 Add to my agenda
03:15 PM
    L   
A comparison of predictors for high grade CIN in the triage of women with abnormal smears
Anne Szarewski [Abstract]
London, UK
517a
 Add to my agenda
02:00 PM
Oral Communications - Epidemiology & Public Health 8
Chair(s):
Lauri Markowitz, Atlanta, USA
Jack Cuzick, London, United Kingdom
 524
 Show details
02:00 PM
    L   
Impact of disparities in HPV vaccine coverage on population-level effectiveness
Marc Brisson [Bio] [Abstract]
Canada Research Chair in Mathematical Modeling and Health Economics of Infectious Disease Social and preventive Medicine, Université Laval
Québec, Canada
524
 Add to my agenda
02:15 PM
    L   
Cervical HPV prevalence in five continents: meta-analysis on one million women with normal cytology
Laia Bruni [Abstract]
Hospitalet de Llobregat , Spain
524
 Add to my agenda
02:30 PM
    L   
Actual and perceived risk of HPV-related disease and intent to receive the HPV vaccine
Elise J. Simons [Abstract]
Rochester, USA
524
 Add to my agenda
02:45 PM
    L   
HPV burden and genotype distribution in anogenital cancers worldwide
Silvia de Sanjosé [Abstract]
L'Hospitalet del Llobregat, Spain
524
 Add to my agenda
03:00 PM
    L   
MODELING THE INCREMENTAL IMPACT OF VACCINATING BOYS AGAINST HPV
Nicolas Van de Velde [Abstract]
Quebec, Canada
524
 Add to my agenda
03:15 PM
    L   
An integrated, functioning cervical cancer prevention strategy in Scotland
Heather A. Cubie [Abstract]
Edinburgh, UK
524
 Add to my agenda
02:00 PM
Oral Communications - Capacity Building
Chair(s):
Neerja Bhatla, New Delhi, India
Lorraine Elit, Hamilton, Canada
 516bcd
 Show details
02:00 PM
    L   
Preventing Cervical Cancer in Rural India: A NGO/ Trust Collaboration
Shobha Krishnan [Abstract]
New York, U.S.A
516bcd
 Add to my agenda
02:12 PM
    L   
Introducing human papillomavirus (HPV) vaccination for adolescent girls: approaches to mobilizing communities for maximum reach
Lysander Menezes [Abstract]
New Delhi, India
516bcd
 Add to my agenda
02:24 PM
    L   
Engaging Youth: A comprehensive health promotion strategy to increase HPV vaccine uptake
Melanie Seguin [Abstract]
Thorold , Canada
516bcd
 Add to my agenda
02:24 PM
    L   
Telemedicine Model of Consultation for Cervical Cancer Prevention
Lorraine Elit [Bio] [Abstract]
Associate Professor, Department of Obstetrics and Gynecology, McMaster University; Gynecologic Oncologist, Juravinski Cancer Centre, Hamilton Health Sciences - Henderson Hospital site
Hamilton, Canada
516bcd
 Add to my agenda
02:36 PM
    L   
Knowledge of Quebec nurses on HPV immunization program before and after a training session
Chantal Sauvageau [Bio] [Abstract]
Beauport, Canada
516bcd
 Add to my agenda
02:48 PM
    L   
HPV Prevention and Cervical Screening Awareness: Developing A Youth-Focused Campaign in Nova Scotia.
Janice Dempsey-Stewart [Abstract]
Dartmouth,, Canada
516bcd
 Add to my agenda
03:00 PM
    L   
WHO/ICO Information Centre on HPV and Cervical Cancer: 3-year usage analysis
Xavier Castellsagué [Abstract]
Unit Chief, Cancer Epidemiology Research Program (CERP)/ Institut Català d'Oncologia (ICO)
Catalonia, Spain
516bcd
 Add to my agenda
03:12 PM
    L   
Updated information in the CDC STD Treatment Guidelines on HPV and Genital Warts, 2010
Eileen Dunne [Abstract]
Atlanta, US
516bcd
 Add to my agenda
04:00 PM
Oral Communications - Basic Science 9
Chair(s):
Douglas R. Lowy, Bethesda, USA
Alison McBride, Bethesda, USA
 517b
 Show details
04:00 PM
    L   
HPV31 and HPV16 induce different signaling cascades at the keratinocyte plasma membrane consistent with disparate initial entry mechanisms
Michelle A. Ozbun [Abstract]
Professor of Molecular Genetics and Microbiology, Molecular Genetics and Microbiology, University of New Mexico
Albuquerque, USA
517b
 Add to my agenda
04:15 PM
    L   
Endpoint maturation of the HPV16 capsid
Chris Buck [Abstract]
Bethesda, USA
517b
 Add to my agenda
04:30 PM
    L   
structures of HPV16 and HPV18 capsids complexed with heparin oligomers
Martin Sapp [Abstract]
Shreveport, USA
517b
 Add to my agenda
04:45 PM
    L   
Nuclear export of HPV31 E1 is regulated by phosphorylation and required for genome maintenance
Amélie Fradet-Turcotte [Abstract]
Montreal, Canada
517b
 Add to my agenda
05:00 PM
    L   
Enhancement of HPV-16 early mRNA splicing by ASF/SF2 is antagonised by SRp30c, a specific inducer of L1 mRNA production
Monika Somberg [Abstract]
Uppsala, Sweden
517b
 Add to my agenda
05:15 PM
    L   
Association of HPV16 L1, L2 and pseudovirions with E1^E4 facilitates completion of the HPV life cycle.
Pauline McIntosh [Abstract]
London, UK
517b
 Add to my agenda
04:00 PM
Oral Communications - Clinical Science 9
Chair(s):
Magnus von Knebel Doeberitz, Heidelberg, Germany
Simon Dobson, Vancouver, Canada
 517a
 Show details
04:00 PM
    L   
Efficacy of the quadrivalent HPV vaccine to prevent anal intraepithelial neoplasia among young men who have sex with men
Joel Palefsky [Bio] [Abstract]
Professor of Medicine, UCSF School of Medicine
San Francisco, USA
517a
 Add to my agenda
04:15 PM
    L   
Impact of the quadrivalent HPV6/11/16/18 vaccine in women who have undergone definitive therapy: do these women benefit from vaccination?
Elmar Joura [Abstract]
Vienna, Austria
517a
 Add to my agenda
04:30 PM
    L   
End of study efficacy of the quadrivalent HPV vaccine against HPV 6/11/16/18-related persistent infection and disease in women aged 24 to 45
Daron Ferris [Abstract]
Augusta, USA
517a
 Add to my agenda
04:45 PM
    L   
Efficacy of a bivalent HPV 16/18 vaccine for prevention of 1-year HPV persistence by age group and sexual history: randomized trial in Guanacaste, Costa Rica
Herrero Rolando [Abstract]
Rockville, USA
517a
 Add to my agenda
05:00 PM
    L   
Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against non-vaccine oncogenic HPV types: end-of-study results
Barbara Romanowski [Abstract]
Edmonton, Canada
517a
 Add to my agenda
05:15 PM
    L   
Comparison of the APTIMA HPV® mRNA Assay with the Hybrid Capture 2® HPV DNA Assay and Cytology in Cervical Cancer Screening
Joseph Monsonego [Abstract]
Medical Director, Institute of the Cervix; President of EUROGIN and WACC International Foundation
Paris, France
517a
 Add to my agenda
04:00 PM
Oral Communications - Epidemiology & Public Health 9
Chair(s):
Gary M. Clifford, Lyon, France
 524
 Show details
04:00 PM
    L   
Mapping the global epidemiology of HPV infection: the continuing series of IARC HPV Prevalence Surveys
Silvia Franceschi [Bio] [Abstract]
Head, Infections and Cancer Epidemiology Group Head, Section of Infections, International Agency for Research on Cancer
Lyon, France
524
 Add to my agenda
04:15 PM
    L   
The dynamics of HPV infection are mainly driven by female-to-male transmission: implications for vaccinating boys
Johannes Bogaards [Abstract]
Amsterdam, The Netherlands
524
 Add to my agenda
04:30 PM
    L   
Modelling the influence of screening uptake on the future incidence of cervical cancer and the cost-effectiveness of HPV vaccination
Johannes Berkhof [Abstract]
Amsterdam, the Netherlands
524
 Add to my agenda
04:45 PM
    L   
Smaller population-level impact of HPV vaccines on HPV-16/18 compared to HPV-6/11: what are the implications
Marie-Claude Boily [Abstract]
London, UK
524
 Add to my agenda
05:00 PM
    L   
Cost-effectiveness for HPV vaccine introduction decisions in low and middle income countries: WHO guidance on existing decision tools
Raymond Hutubessy [Abstract]
Geneva, Switzerland
524
 Add to my agenda
05:15 PM
    L   
Racial Disparities in Cervical Cancer Treatment and Survival in the United States
Candace Sirjoosingh [Abstract]
Montreal, Canada
524
 Add to my agenda
04:00 PM
Satellite Symposium - HPV & cervical cancer in Latin America (presentations in English)
More Details...
Chair(s):
Paulo Naud, Porto Alegre, Brazil
Silvio Tatti, Buenos Aires, Argentina
 516abc
 Add to my agenda
07:00 PM
Evening event - Banquet
 Windsor Station
 Add to my agenda